Holen Sie sich die Stockscreener-App
1.75
9.33%
-0.18
Handel nachbörslich:
1.72
-0.03
-1.71%
Schlusskurs vom Vortag:
$1.93
Offen:
$1.95
24-Stunden-Volumen:
4.42M
Relative Volume:
3.03
Marktkapitalisierung:
$55.22M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.00M
KGV:
-0.6295
EPS:
-2.78
Netto-Cashflow:
$-55.26M
1W Leistung:
-28.86%
1M Leistung:
-29.72%
6M Leistung:
+30.60%
1J Leistung:
-71.31%
1-Tages-Spanne:
$1.75
$2.02
1-Wochen-Bereich:
$1.75
$3.56
52-Wochen-Spanne:
$1.05
$8.00
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Firmenname
Acrivon Therapeutics Inc
Sektor
Branche
Telefon
617-207-8979
Adresse
480 ARSENAL WAY, SUITE 100, WATERTOWN
Vergleichen Sie ACRV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
1.75 | 60.90M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-05 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-01-31 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2024-09-16 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-12-15 | Fortgesetzt | Jefferies | Buy |
| 2023-10-05 | Eingeleitet | Maxim Group | Buy |
| 2023-06-02 | Eingeleitet | Oppenheimer | Outperform |
| 2023-05-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-04-27 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2023-04-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-12-12 | Eingeleitet | Cowen | Outperform |
| 2022-12-12 | Eingeleitet | Jefferies | Buy |
| 2022-12-12 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Acrivon Therapeutics Inc Aktie (ACRV) Neueste Nachrichten
Acrivon Therapeutics Spotlights ACR368 Endometrial Cancer Data, Adds Serous Arm 3 and FDA Phase 3 Plan - Defense World
Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data - Investing.com
Acrivon reports 52% response rate in serous endometrial cancer trial By Investing.com - Investing.com Nigeria
How Acrivon Therapeutics Inc. stock compares to market leadersM&A Rumor & Long-Term Safe Investment Plans - ulpravda.ru
What is the fair value of Acrivon Therapeutics Inc. stock nowJuly 2025 Sector Moves & Verified Chart Pattern Signals - ulpravda.ru
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - Sahm
Why Acrivon Therapeutics Inc. stock could rally in 2025Treasury Yields & Community Consensus Picks - ulpravda.ru
Treasury Yields: Can Acrivon Therapeutics Inc. stock resist market sell offsWeekly Trade Summary & High Accuracy Investment Entry Signals - ulpravda.ru
Acrivon Therapeutics Inc. (ACRV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why Acrivon Therapeutics Inc. stock remains a top recommendationInflation Watch & Fast Moving Market Watchlists - ulpravda.ru
Why retail investors pile into Acrivon Therapeutics Inc. stockSwing Trade & Long-Term Growth Stock Strategies - ulpravda.ru
Small-Cap Acrivon Showcases Tumor Reduction and Clinical Advancement in Major Trials, Shares Decline - Bitget
Acrivon Therapeutics Inc.: Rise or Retreat? - StocksToTrade
Acrivon Stock Sinks 29% Despite Positive Phase 2b Endometrial Cancer Data - Nasdaq
Aug Gainers: What is the fair value of Acrivon Therapeutics Inc. stock now2025 Key Lessons & High Accuracy Trade Signal Alerts - ulpravda.ru
Focused Clinical Strategy and Accelerated Approval Path for ACR-368 in High-Need Serous Endometrial Cancer Underpin ACRV Buy Rating - TipRanks
Exit Recap: Why retail investors pile into Acrivon Therapeutics Inc. stockOptions Play & Safe Entry Point Alerts - ulpravda.ru
Why Is Acrivon Therapeutics Stock Falling Today?Acrivon Therapeutics (NASDAQ:ACRV) - Benzinga
Dow Jumps Over 250 Points; US Initial Jobless Claims Increase - Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
What momentum indicators show for Acrivon Therapeutics Inc. stockQuarterly Profit Review & Verified Short-Term Plans - ulpravda.ru
Acrivon Therapeutics announces progress across pipeline - TipRanks
Nasdaq Falls Over 100 Points; Acuity Posts Upbeat Earnings - Benzinga
Acrivon Therapeutics stock plunges after mixed cancer trial results By Investing.com - Investing.com South Africa
Acrivon Therapeutics stock plunges after mixed cancer trial results - Investing.com
Is Acrivon Therapeutics Inc. stock overvalued by current metrics2025 Retail Activity & AI Enhanced Trading Alerts - ulpravda.ru
Acrivon Showcases Promising Phase 2b Oncology Data Update - TipRanks
Acrivon Therapeutics Stock (ACRV) Opinions on Clinical Data Release - Quiver Quantitative
Acrivon's ACR-368 Shows 52% Response Rate In Endometrial Cancer, Expands Trial To Europe - Nasdaq
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data - TipRanks
New cancer drugs show tumor shrinkage in early trials - Stock Titan
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Why AZZ Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
Acrivon to provide clinical updates on cancer drug candidates By Investing.com - Investing.com Nigeria
Acrivon To Deliver Clinical Updates On ACR-368 And ACR-2316 Tomorrow; Stock Soars - Nasdaq
Acrivon Therapeutics to announce clinical update on Phase 2b ACR-368 studies - TipRanks
Acrivon Therapeutics to announce clinical update on phase 2b ACR-368 studies - MSN
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Acrivon Therapeutics to Release Clinical Data Updates on ACR-368 and ACR-2316 on January 8, 2026 - Quiver Quantitative
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast - The Manila Times
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Head-To-Head Contrast: Acrivon Therapeutics (NASDAQ:ACRV) versus Ernexa Therapeutics (NASDAQ:ERNA) - Defense World
Is Acrivon Therapeutics Inc a good long term investmentEarnings Volatility Patterns & Multiply Your Assets With Time-Tested Picks - earlytimes.in
Trend Recap: Why retail investors pile into Acrivon Therapeutics Inc stockWeekly Stock Summary & Weekly Watchlist for Hot Stocks - moha.gov.vn
H.C. Wainwright Initiates Coverage on Acrivon Therapeutics (ACRV) With “Buy” Rating and $19 PT - MSN
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Sahm
Is Acrivon Therapeutics Inc. stock attractive for long term wealth buildingWeekly Trade Analysis & Growth-Oriented Investment Plans - Улправда
Acrivon Therapeutics (NASDAQ:ACRV) Rating Increased to Hold at Wall Street Zen - MarketBeat
Finanzdaten der Acrivon Therapeutics Inc-Aktie (ACRV)
Umsatz
Nettogewinn
Free Cashflow
ENV
Acrivon Therapeutics Inc-Aktie (ACRV) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 10% Owner |
May 01 '25 |
Sale |
1.34 |
298,886 |
400,507 |
3,104,139 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 25 '25 |
Sale |
1.95 |
1,054,669 |
2,056,605 |
4,306,189 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 29 '25 |
Sale |
1.41 |
250,000 |
352,500 |
3,840,906 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 28 '25 |
Sale |
1.56 |
215,283 |
335,841 |
4,090,906 |
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):